Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer

September 30, 2021 2:05 am

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.


By The ASCO Post Staff

For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely to benefit from the drug. In a study published by Panagiotis Konstantinopoulos, MD, PhD, and colleagues in the journal Nature Communications, the researchers identified a biomarker—a genetic signature within ovarian cancer cells—indicating the cells are experiencing “high replication stress” (RS-high). Cells in this state, struggling to replicate their DNA at high speed, are especially susceptible to gemcitabine, the researchers found.

Panagiotis Konstantinopoulos, MD, PhD
Panagiotis Konstantinopoulos, MD, PhD

The discovery was followed by another that came as a surprise: in patients whose tumor cells had high replication stress, a combination of gemcitabine and a complementary agent was no more effective than gemcitabine alone. Equally surprising was the discovery that tumors with low replication stress responded poorly to gemcitabine alone but did respond to the two-agent therapy.

The findings offer a way for doctors to identify patients with high-grade serous ovarian cancer who stand to benefit from the combination therapy and those for whom gemcitabine works well on its own. Investigators are planning a large, phase III clinical trial comparing gemcitabine to the tandem therapy in this group of patients, hoping to confirm the findings of the Nature Communications study.

“Patients with high-grade serous ovarian cancer that has become resistant to platinum-based chemotherapy drugs have a compelling need for better treatments,” said first and corresponding study author Dr. Konstantinopoulos, of Dana-Farber Cancer Institute. “A new class of compounds called ATR inhibitors, which target the DNA-replication process in rapidly dividing cancer cells, have shown a great deal of promise in laboratory studies.”

“In a previous clinical trial, our group showed that a combination of gemcitabine and the ATR inhibitor berzosertib enabled many patients with high-grade serous ovarian cancer to live substantially longer before their disease worsened than patients treated with gemcitabine alone,” he continued. “For the current study, we looked for a biomarker that could predict response to the therapy.”

More on Replication Stress and ATR

Replication stress is a byproduct of the amped-up pace of cell growth and division in many tumors. While faster growth confers certain advantages, it also puts enormous strain on the portion of the cell cycle in which cells copy their DNA prior to dividing. A cell racing to duplicate its DNA is apt to make more mistakes than one functioning at normal speed. The accumulation of miscopied strands of DNA represents a direct threat to a tumor’s future: without an intact genetic code, its constituent cells are ill-equipped to survive.

Amid this unbridled haste and error, the ATR protein exerts a steadying, meticulous influence. It halts the cell cycle so DNA can be checked for mistakes and summons other proteins to make the necessary corrections. ATR’s importance to cancer cells’ survival makes it an appealing target for therapy.

Dr. Konstantinopoulos and his colleagues put that strategy to the test in their earlier clinical trial. The hypothesis was that the combination of gemcitabine and berzosertib would undermine DNA replication to a point that would be lethal to cancer cells.

The trial was largely a success, with many patients benefiting from the dual therapy. For the new study, researchers analyzed tumor samples from 57 patients who participated in the trial, looking for mutations or alterations in hundreds of genes. They found that RS-high tumors carried any of eight abnormalities—including the loss of the genes RB1 or CDKN2A or surplus copies of the genes CCNE1, KRAS, or MYC. Tumors without any of these flaws were considered RS-low.

Our discovery of a novel biomarker for response to gemcitabine in patients with high-grade serous ovarian cancer is an important step in personalizing treatment for this disease.

— Panagiotis Konstantinopoulos, MD, PhD

The study’s follow-up finding—that RS-high tumors respond no better to gemcitabine plus berzosertib than they do to gemcitabine alone, whereas RS-low tumors are more susceptible to the combination—at first seems contradictory. Dr. Konstantinopoulos explains the results this way: “In cells with high replication stress, gemcitabine creates enough additional stress that the cells die. In cells with low replication stress, gemcitabine increases the stress, but not to the point where they die. The addition of an ATR inhibitor brings the stress up to the necessary lethality level.”

He concluded: “Our discovery of a novel biomarker for response to gemcitabine in patients with high-grade serous ovarian cancer is an important step in personalizing treatment for this disease. We’re eager to validate this finding in the new clinical trial currently being planned.”

Disclosure: This study was funded by the National Cancer Institute-Cancer Therapy Evaluation. It was also supported by the National Institutes of Health and by the Dana-Farber/Harvard Cancer Center Specialized Program of Research Excellence in Ovarian Cancer. For full disclosures of the study authors, visit

This article was published by ASCO Post.

Leave a Reply

Your email address will not be published. Required fields are marked *

Return to Blog Home Return to Clearity Foundation Home